The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer

被引：0
|
作者：
Suh, Kangho
Carlson, Josh John
Xia, Fang
Williamson, Todd E.
Sullivan, Sean D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 981 - 986
  • [3] Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Narita, Yukiya
    Tsushima, Takahiro
    Ishihara, Makoto
    Todaka, Akiko
    Tanaka, Tsutomu
    Yokota, Tomoya
    Kadowaki, Shigenori
    Machida, Nozomu
    Ura, Takashi
    Fukutomi, Akira
    Ando, Masashi
    Onozawa, Yusuke
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Mori, Keita
    Yamazaki, Kentaro
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E15 - E22
  • [4] The patential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma
    Suh, Kangho
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06): : 622 - 630
  • [5] Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)
    Grell, Peter
    Borilova, Simona
    Schwanzerova, Renata
    Kukolikova, Sabina
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Buchler, Tomas
    Selingerova, Iveta
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Kiss, Igor
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"
    Ogale, Sarika
    Zerbini, Clarissa Emy Higuchi
    Antoniou, Miranta
    Freund, Romain
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1616 - 1617
  • [7] Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    CLINICAL THERAPEUTICS, 2020, 42 (07) : 1376 - 1387
  • [8] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER" RESPOND
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1617 - 1618
  • [9] Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer
    Carlson, Josh J.
    Italiano, Antoine
    Brose, Marcia S.
    Federman, Noah
    Lassen, Ulrik
    Kummar, Shivaani
    Sullivan, Sean D.
    AMERICAN JOURNAL OF MANAGED CARE, 2022, 28 (02): : S26 - S32
  • [10] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
    Victorino, Ana Paula Ornellas S.
    Meton, Fernando
    Mardegan, Luciana
    Festa, Juliana
    Piranda, Diogo N.
    Araujo, Kelly Borges
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
12345